Sure is going into winter.
Printable View
This was caused by COVID-19 related travel and
freight restrictions, along with a four-month shut down of the
Company’s largest freeze dryer to install an additional dryer
without overseas engineering support
We are
seeing potential for some of the strongest demand in our
history and decisions to progress with expansion plans during
the pandemic mean we are well positioned to take advantage
of increased opportunities.
Pleasing seeing "well positioned."
Why they write off $306,330 of inventory.
We also have a number of other well researched and considered new product
development opportunities that the Board is very excited by. These opportunities,
coupled with continuing strong demand for our existing products, an easing of
border restrictions and our newly developed engineering capabilities, position
PharmaZen for substantially better growth in 2022.
($813,600) Loss after tax, Ouch ! Just as well according to some, earnings don't matter and its all about the future.
Has anyone looked into the impact of the convertible notes converting to shares? In particular the impact on EPS?